Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5453510 | ABBVIE | Neuromuscular blocking agents |
Sep, 2012
(11 years ago) |
Nimbex is owned by Abbvie.
Nimbex contains Cisatracurium Besylate.
Nimbex has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Nimbex are:
Nimbex was authorised for market use on 15 December, 1995.
Nimbex is available in injectable;injection dosage forms.
Nimbex can be used as method of producing neuromuscular blockade.
The generics of Nimbex are possible to be released after 26 September, 2012.
Drugs and Companies using CISATRACURIUM BESYLATE ingredient
Market Authorisation Date: 15 December, 1995
Treatment: Method of producing neuromuscular blockade
Dosage: INJECTABLE;INJECTION